RESEARCH ANTIBODIES MARKET ANALYSIS

Research Antibodies Market, By Product Type (Primary Antibodies, Secondary Antibodies, Reagents, Consumables), By Form (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies), By Application (Western Blotting, ELISA , Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry), Others), By End User (Academic & Research Institutes, Contract Research Organizations, Pharmaceutical & Biotechnology Companies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

On May 30, 2024, Scientists from Texas Biomedical Research Institute, the University of Alabama at Birmingham, and Columbia University developed a human monoclonal antibody effective against multiple strains of SARS-CoV-2. Led by Dr. Luis Martinez-Sobrido, the research offers promise for a universal antibody, as it demonstrated efficacy against the original SARS-CoV-2, Omicron, and SARS-CoV. This breakthrough, published on BioRXiv, suggests potential for future strain defense when combined with other antibodies.
In February 2022, Abcam, Biotechnology company, announced its collaboration with Twist Bioscience, a leading provider of synthetic DNA, aiming to enhance antibody discovery for diagnostic and research applications
In February 2022, Merck Millipore a life science company announced its acquisition of Exelead for approximately US$ 780 million. This acquisition enables Merck's Life Science business division to offer end-to-end CDMO services across the mRNA value chain to its customers.
In November 2021, Nautilus Biotechnology a development stage life sciences company announced a strategic agreement with Abcam to accelerate research and development of the Proteome. This agreement grants Nautilus Biotechnology's customers access to Abcam's antibody development technology and expertise.